---
title: "Cidara Therapeutics Completes Acquisition and Becomes Private Company"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/271805051.md"
description: "Cidara Therapeutics has completed its acquisition, becoming a private company after a cash tender offer for approximately 88.3% of its voting shares. The merger resulted in the termination of its equity plans, delisting from Nasdaq, and a change in management. The latest analyst rating for CDTX stock is a Hold with a price target of $232. Despite financial challenges, positive developments and strategic events suggest potential future growth."
datetime: "2026-01-07T14:31:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/271805051.md)
  - [en](https://longbridge.com/en/news/271805051.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/271805051.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/271805051.md) | [繁體中文](https://longbridge.com/zh-HK/news/271805051.md)


# Cidara Therapeutics Completes Acquisition and Becomes Private Company

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

An announcement from Cidara Therapeutics ( (CDTX) ) is now available.

On January 7, 2026, following the expiration of a tender offer the previous day, a purchaser entity completed a cash tender for approximately 88.3% of Cidara Therapeutics’ voting shares, then merged with and into Cidara under Delaware law, making Cidara a wholly owned subsidiary of the acquiring parent. As part of the transaction, all remaining common and Series A shares were converted into cash consideration, existing stock options, restricted stock units and warrants were either cashed out or cancelled in accordance with their terms, Cidara terminated its equity and employee stock purchase plans, its Nasdaq-listed shares were halted, delisted and prepared for deregistration with the SEC, and the company’s board, management and governing documents were replaced by those of the purchaser, effectively completing Cidara’s transition to a private, parent-controlled entity.

The most recent analyst rating on (CDTX) stock is a Hold with a $232.00 price target. To see the full list of analyst forecasts on Cidara Therapeutics stock, see the CDTX Stock Forecast page.

**Spark’s Take on CDTX Stock**

According to Spark, TipRanks’ AI Analyst, CDTX is a Neutral.

Cidara Therapeutics’ overall stock score is driven by significant financial challenges and a negative valuation outlook. However, strong technical momentum, positive earnings call developments, and strategic corporate events like the merger with Merck provide a counterbalance, indicating potential future growth and value.

To see Spark’s full report on CDTX stock, click here.

**More about Cidara Therapeutics**

Cidara Therapeutics operates in the biopharmaceutical industry, developing and commercializing therapeutic products, and has been a publicly listed company with common stock and Series A preferred shares previously traded on Nasdaq and governed by multiple equity incentive and employee stock purchase plans.

**Average Trading Volume:** 1,384,277

**Technical Sentiment Signal:** Buy

**Current Market Cap:** $6.96B

Learn more about CDTX stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [Cidara Therapeutics, Inc. (CDTX.US)](https://longbridge.com/en/quote/CDTX.US.md)

## Related News & Research

- [Cidara Therapeutics Announced Transfer or Voluntary Withdrawal of Listing](https://longbridge.com/en/news/271801210.md)
- [Stempoint Capital LP Takes Position in Cidara Therapeutics, Inc. $CDTX](https://longbridge.com/en/news/269230127.md)
- [Culpeo Minerals Sets May 7 AGM and Urges Early Proxy Voting](https://longbridge.com/en/news/281449270.md)
- [Maire Discloses Record-Date Voting Structure Ahead of April Shareholders’ Meeting](https://longbridge.com/en/news/281558650.md)
- [MEKO calls 2026 AGM with in-person and postal voting options](https://longbridge.com/en/news/281364262.md)